3-dimethylaminopropiononitrile

Repeated dose toxicity: inhalation

Administrative data

Endpoint:

short-term repeated dose toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Study report which meets basic scientific principles

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1989

Report date:

1989

Materials and methods

Principles of method if other than guideline:

14-day screening study with rats to detect neuropathological changes; due to missing test parameters no AEC was identifiable.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

3-dimethylaminopropiononitrile

EC Number:

217-090-4

EC Name:

3-dimethylaminopropiononitrile

Cas Number:

1738-25-6

Molecular formula:

C5H10N2

IUPAC Name:

3-(dimethylamino)propanenitrile

Details on test material:

- Name of test material (as cited in study report): Dimethylaminopropionitril, DMAPN
- Physical state: liquid
- Analytical purity: ca. 98%
- Stability under test conditions: at least 2 years
- Storage condition of test material: room temperature

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Age at study initiation: 9 weeks
- Mean group weight at study initiation: males 265-299 g, females 178-190g
- Housing: single, in cage type MDIII
- Diet (ad libitum): Kliba Labordiaet Ratte/Maus Haltungsfutter, Kliba 24-343-4, 10 mm Pellets, Klingenthalmuehle AG, Kaiseraugst
- Water (ad libitum): tap water
- Acclimation period: 2 weeks


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:

inhalation: vapour

Type of inhalation exposure:

whole body

Vehicle:

other: unchanged (no vehicle)

Analytical verification of doses or concentrations:

yes

Duration of treatment / exposure:

2 weeks

Frequency of treatment:

6 h/d, 5d/week

Doses / concentrations

Remarks:

Doses / Concentrations:
0 ; 0.01 ; 0.1 and 1 mg/L
Basis:
analytical conc.

No. of animals per sex per dose:

5

Control animals:

yes, concurrent no treatment

Details on study design:

Drift start without exposition was one week before treatment.

Examinations

Observations and examinations performed and frequency:

Body weight: at drift start one week before test start, at test start and every second day exept on weekends.
Clinical signs: on work days
Mortality: daily
Urinanalysis: on day 13/14

Sacrifice and pathology:

GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes

Results and discussion

Results of examinations

Details on results:

CLINICAL SIGNS AND MORTALITY
No mortality was observed. Clinical signs were unspecific and restricted to the highest dose group: upright respiration position.

BODY WEIGHT AND WEIGHT GAIN
Reduced body weight gain in males of the highest dose group.

URINALYSIS
no clear substance related effects

NEUROBEHAVIOUR
Reduced startle response in males of the highest dose group.

GROSS PATHOLOGY
no substance related effects

HISTOPATHOLOGY: NON-NEOPLASTIC
no substance related effects

Effect levels

Dose descriptor:

NOAEC

Basis for effect level:

other: No NOAEC has been identified

Remarks on result:

not determinable

Remarks:

no NOAEC identified

Target system / organ toxicity

Critical effects observed:

not specified